PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Articles
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Articles
  • Our team
  • Join us

Evolve’s Steven Gurney recognised in IAM 1000 2025

  • Sector: Uncategorized
  • 11th June 2025
We are delighted to announce that Evolve's founder Steven Gurney has once again be recognised in the IAM patent 1000.

We are delighted to announce that Evolve’s founder Steven Gurney has once again be recognised in the IAM patent 1000. The IAM Patent 1000 rankings consider various factors such as expertise depth, market positioning, and positive feedback from both peers and clients.

A highly skilled life science patent attorney with over 20 years of combined in-house and private practice experience, Steven’s expertise spans pharmaceuticals, drug development and IP, drafting, portfolio management and prosecution, lifecycle management, licensing (in- and out-), due diligence and FTO, and contentious work.

We are grateful to IAM for once again highlighting Evolve in their Patent 1000 2025 Guide. We deeply appreciate our clients’ continued support and confidence, which has enabled this achievement.

Related insights...

Launch of Evolve Webinars!

  • 25th June 2025
A series of live webinars on IP strategy for pharma & biotech professionals.

Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy

  • 27th May 2025
Navigating European pharma and biotech patent litigation is more complex than ever, with ongoing debates on plausibility, UPC intricacies, claim interpretation, and divergent strategies for antibody inventions.

Rose Hughes joins Evolve

  • 7th May 2025
Evolve Intellectual Property is pleased to welcome Dr. Rose Hughes as our new Patent Attorney.

Evolve joins the ranks of the Legal 500

  • 1st November 2024
We are delighted to announce that Evolve has joined the ranks of the Legal 500 Intellectual Property firms. The Legal 500 is one of the UK’s leading legal directories, known for its rigorous research methodology and independent analysis of the legal market. As a small boutique IP firm, we are particularly proud of this achievement. …
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Subscribe

Contact Us